Medical Pharmacology: Chapter 32 — Hypothalamic Pharmacology -- Module 2

Chapter 32 — Hypothalamic Pharmacology — Module 2 — GnRH Analogs in Clinical Practice

1. A 73-year-old man presents to the emergency department with severe low back pain and new lower-extremity weakness. Imaging reveals extensive vertebral metastases with epidural tumor abutting the spinal cord at T11, and biopsy confirms metastatic prostate adenocarcinoma. His PSA is 240 ng/mL. The oncology and spine teams plan urgent radiotherapy and want to begin androgen deprivation immediately. Which of the following is the most appropriate pharmacologic strategy for initiating androgen deprivation in this patient?

A) Begin leuprolide depot alone today, because rapid initiation of any androgen deprivation agent takes priority and the depot formulation prevents a clinically meaningful testosterone surge
B) Begin goserelin implant alone today, because its subcutaneous route produces faster and flare-free testosterone suppression than other agonist formulations
C) Begin a GnRH antagonist such as degarelix today, because it suppresses testosterone within about 3 days with no testosterone flare, avoiding the agonist-induced surge that could worsen epidural disease and precipitate spinal cord compression in this patient
D) Begin leuprolide depot today together with calcium and vitamin D, deferring anti-androgen coverage because bone-protective supplementation mitigates the consequences of the flare
E) Defer all androgen deprivation until radiotherapy is complete, because starting any hormonal therapy during active cord compression is contraindicated

ANSWER: C

Rationale:

This patient has epidural metastatic disease abutting the spinal cord and early neurologic deficit — a setting in which a testosterone flare could precipitate or worsen spinal cord compression, a neurologic emergency. GnRH agonists produce a testosterone surge of 50 to 80% above baseline during the first 1 to 2 weeks because initial receptor activation drives an LH and FSH surge before downregulation occurs. A GnRH antagonist such as degarelix competitively blocks the GnRH receptor from the first dose, suppressing testosterone to castrate levels in more than 96% of patients within about 3 days with no flare. This makes the antagonist the safest and most effective way to begin androgen deprivation rapidly in this high-risk patient. (If an agonist had to be used, anti-androgen flare coverage begun before the agonist would be mandatory, but the antagonist avoids the flare entirely and acts faster.)

Option A: Option A is incorrect because all GnRH agonist depots, regardless of formulation, produce a testosterone flare; the depot kinetics do not prevent the initial receptor activation surge, so leuprolide alone would be dangerous here.
Option B: Option B is incorrect because goserelin is a GnRH agonist; despite its subcutaneous implant route, it shares the agonist flare and the delayed onset of castration (about 21 to 28 days), so it is neither faster nor flare-free.
Option D: Option D is incorrect because calcium and vitamin D protect bone density over the long term but do nothing to prevent the acute testosterone flare or the resulting risk of cord compression; they are not a substitute for an antagonist or anti-androgen coverage.
Option E: Option E is incorrect because androgen deprivation should not be deferred in metastatic hormone-sensitive prostate cancer with cord compression; prompt testosterone suppression is part of management, and the flare risk is handled by choosing an antagonist rather than by withholding therapy.

2. A 70-year-old man with metastatic prostate cancer has been receiving leuprolide depot every 3 months for 2 years. His PSA, previously undetectable, has risen to 3.1 ng/mL over two visits. A testosterone level drawn just before his next scheduled injection is 72 ng/dL. Examination shows that all injections have been administered into the same firm, indurated area of the right gluteal region. Which of the following is the most appropriate interpretation and next step?

A) He has developed castration-resistant prostate cancer; the leuprolide should be stopped because it is no longer effective and the rising PSA reflects androgen-independent progression
B) The testosterone of 72 ng/dL is acceptable and within castrate range; the PSA rise should be addressed by adding an anti-androgen without altering the GnRH agonist
C) The result reflects laboratory error, since depot agonist therapy reliably maintains testosterone below 50 ng/dL in all patients; the test should be repeated with no other action
D) He has developed neutralizing antibodies to leuprolide; he should be switched to a structurally distinct GnRH agonist to overcome the immune response
E) This is non-castrate testosterone on depot agonist therapy, most likely from impaired drug absorption at the fibrotic injection site; appropriate steps include verifying and correcting injection technique, rotating to fresh injection sites, and considering a switch to a GnRH antagonist such as degarelix or relugolix, which maintain castrate levels more consistently

ANSWER: E

Rationale:

A serum testosterone of 72 ng/dL is above the castration threshold (below 50 ng/dL traditionally, below 20 ng/dL by newer guidelines) and represents non-castrate testosterone on depot agonist therapy, which occurs in roughly 4 to 13% of patients. The rising PSA together with repeated injections into a single fibrotic site points to impaired drug absorption from injection-site fibrosis as the likely cause; other causes include incorrect injection technique and end-of-dose escape. The appropriate next steps are to verify and correct injection technique, rotate to fresh sites, and consider switching to a GnRH antagonist (degarelix or relugolix), which maintains castrate testosterone more consistently.

Option A: Option A is incorrect because castration-resistant prostate cancer is defined by progression despite confirmed castrate testosterone; with a testosterone of 72 ng/dL, castration has not been achieved, so this does not meet the definition, and abandoning the agonist before restoring adequate suppression is premature.
Option B: Option B is incorrect because 72 ng/dL is not within castrate range by any standard; adding an anti-androgen without restoring castrate testosterone leaves the underlying suppression failure unaddressed.
Option C: Option C is incorrect because non-castrate testosterone on depot therapy is a recognized clinical entity, not merely laboratory error; the fibrotic injection site provides a clear mechanism, and dismissing the result risks missing a correctable problem.
Option D: Option D is incorrect because clinically significant neutralizing antibodies to leuprolide are not an established mechanism of treatment failure; the far more likely explanation here is a pharmacokinetic delivery problem at the fibrotic site, addressed by technique correction, site rotation, or switching to an antagonist.

3. A 36-year-old woman with biopsy-confirmed endometriosis has been treated with leuprolide depot 3.75 mg monthly for 4 months. Her pelvic pain is well controlled, but she now reports frequent disabling hot flashes, poor sleep, and vaginal dryness, and a repeat DEXA shows a 4% decline in lumbar spine bone mineral density. She wishes to continue effective treatment. Which of the following is the most appropriate management?

A) Stop the leuprolide entirely, because detectable bone loss on GnRH agonist therapy is an absolute indication to discontinue treatment regardless of any adjunctive measures
B) Add add-back therapy, such as norethindrone acetate 5 mg daily or low-dose estrogen plus a progestin, to raise estradiol into approximately the 20 to 40 pg/mL window — high enough to protect bone and relieve vasomotor symptoms but low enough to keep the endometriosis suppressed — allowing continued therapy beyond 6 months without sacrificing pain control
C) Double the leuprolide dose to deepen suppression, which will reduce bone loss by more completely eliminating estrogen-driven activity in the endometriotic implants
D) Add high-dose conjugated estrogen to raise estradiol above 60 pg/mL, since only supraphysiologic estrogen levels can both reverse bone loss and relieve hot flashes
E) Switch to a GnRH antagonist such as degarelix, because antagonists do not cause the hypoestrogenic bone loss and vasomotor symptoms seen with agonists

ANSWER: B

Rationale:

This patient has the predictable hypoestrogenic adverse effects of GnRH agonist therapy — vasomotor symptoms, vaginal dryness, and bone mineral density (BMD) loss — while benefiting from good pain control. The appropriate management is add-back therapy, applying the estrogen threshold principle: endometriosis implants require estradiol above approximately 20 pg/mL to grow, while bone protection requires estradiol above approximately 30 to 40 pg/mL. Add-back (norethindrone acetate 5 mg daily alone, or low-dose estrogen plus a progestin) is dosed to hold estradiol in the roughly 20 to 40 pg/mL window — enough to protect bone and relieve hot flashes but below the threshold that would reactivate the implants. Appropriately dosed add-back does not significantly reduce pain control and allows therapy to continue beyond the 6-month limit that applies without add-back.

Option A: Option A is incorrect because detectable bone loss is not an absolute indication to stop GnRH agonist therapy; the standard solution is to add add-back therapy, which permits safe continuation.
Option C: Option C is incorrect because doubling the leuprolide dose would deepen hypoestrogenism and worsen, not reduce, bone loss; estradiol is already at castrate levels and cannot be lowered further to benefit, while bone protection requires raising estradiol into the add-back window.
Option D: Option D is incorrect because raising estradiol above 60 pg/mL exceeds the implant-stimulation threshold (approximately 20 pg/mL) and would risk reactivating the endometriosis and recurrent pain; the target is the 20 to 40 pg/mL window, not supraphysiologic levels.
Option E: Option E is incorrect because GnRH antagonists used to treat endometriosis also suppress estradiol and produce hypoestrogenic bone loss and vasomotor symptoms; switching from an agonist to degarelix does not avoid these effects, since the mechanism of bone loss is estrogen deprivation shared by both classes.

4. A 32-year-old woman with HIV maintained on a ritonavir-boosted antiretroviral regimen presents with moderate-to-severe endometriosis-associated pelvic pain inadequately controlled by NSAIDs and combined oral contraceptives. Her gynecologist is considering elagolix 200 mg twice daily. Which of the following best describes the most appropriate assessment of this plan?

A) Elagolix and ritonavir do not interact, because elagolix is eliminated primarily by renal excretion of unchanged drug; the 200 mg twice-daily regimen can be started without modification
B) Ritonavir induces CYP3A4, which would lower elagolix exposure and reduce pain control; the elagolix dose should be increased to compensate during antiretroviral therapy
C) The interaction is clinically unimportant because the endometriosis itself accelerates elagolix metabolism, offsetting any effect of ritonavir on drug levels
D) Ritonavir is a strong CYP3A4 inhibitor and elagolix is a major CYP3A4 substrate, so co-administration substantially increases elagolix exposure; the elagolix 200 mg twice-daily dose is contraindicated with strong CYP3A4 inhibitors, and an alternative endometriosis strategy should be selected or the regimen reconsidered with the HIV team
E) Ritonavir increases elagolix clearance through intestinal P-glycoprotein induction, so the elagolix dose must be doubled to maintain efficacy during co-administration

ANSWER: D

Rationale:

Elagolix is metabolized primarily by CYP3A4, and ritonavir is one of the most potent CYP3A4 inhibitors in clinical use. Co-administration substantially increases elagolix plasma concentrations, and the elagolix 200 mg twice-daily dose is specifically contraindicated with strong CYP3A4 inhibitors because the resulting exposure can reach potentially harmful levels. The appropriate course is to avoid the 200 mg twice-daily regimen in this patient and select an alternative endometriosis strategy (for example, the lower elagolix dose with careful consideration of labeling, or a non-GnRH approach), in coordination with the HIV team to avoid compromising antiretroviral therapy.

Option A: Option A is incorrect because elagolix is not eliminated primarily by renal excretion of unchanged drug; it undergoes extensive hepatic CYP3A4 metabolism, which is precisely why the ritonavir interaction is significant.
Option B: Option B is incorrect because ritonavir inhibits rather than induces CYP3A4 at therapeutic doses; it increases elagolix exposure, so raising the dose would compound toxicity.
Option C: Option C is incorrect because endometriosis does not accelerate elagolix metabolism in a way that offsets ritonavir's potent CYP3A4 inhibition; the interaction is clinically important and underlies the contraindication.
Option E: Option E is incorrect because ritonavir does not induce intestinal P-glycoprotein to increase elagolix clearance; the dominant, clinically relevant mechanism is strong CYP3A4 inhibition that raises elagolix exposure, making the 200 mg twice-daily dose contraindicated.

5. A 74-year-old man with advanced prostate cancer is well controlled on oral relugolix 120 mg once daily. He is admitted with new symptomatic atrial fibrillation with rapid ventricular response, and the admitting team is choosing an agent for rate or rhythm control. The oncology pharmacist is consulted to help avoid a harmful drug interaction with his relugolix. Which of the following recommendations is most appropriate?

A) Avoid strong P-glycoprotein inhibitors such as amiodarone and verapamil, because relugolix is a P-glycoprotein substrate and these agents can increase relugolix exposure substantially (up to about 4-fold); a rate-control strategy using an agent that does not strongly inhibit P-glycoprotein, such as a beta-blocker, is preferable, with relugolix otherwise managed per labeling
B) Start amiodarone, because its long half-life provides the most stable rhythm control and it has no clinically significant interaction with relugolix
C) Start verapamil, because calcium channel blockers do not interact with GnRH antagonists and relugolix exposure is unaffected by P-glycoprotein inhibition
D) Double the relugolix dose preemptively before starting any antiarrhythmic, because antiarrhythmic drugs as a class induce relugolix metabolism and reduce its efficacy
E) Discontinue relugolix entirely for the duration of the hospitalization, because no antiarrhythmic agent can be safely co-administered with any GnRH antagonist

ANSWER: A

Rationale:

Relugolix is a substrate of P-glycoprotein (P-gp), and its disposition is governed by P-gp-mediated transport rather than by CYP3A4 metabolism. Strong P-gp inhibitors — including amiodarone and verapamil, both common choices in atrial fibrillation — can increase relugolix exposure substantially (up to about 4-fold), raising the risk of adverse effects. The pharmacist should therefore steer the team away from strong P-gp inhibitors and toward a rate-control agent that does not strongly inhibit P-gp, such as a beta-blocker, while managing relugolix per its labeling. This is a clear example of letting the relugolix interaction profile shape the antiarrhythmic choice.

Option B: Option B is incorrect because amiodarone is a strong P-gp inhibitor and has a clinically significant interaction with relugolix; its long half-life would also prolong any interaction, making it a poor choice here.
Option C: Option C is incorrect because verapamil is a strong P-gp inhibitor and does increase relugolix exposure; the claim that calcium channel blockers do not interact with relugolix is wrong.
Option D: Option D is incorrect because antiarrhythmic drugs do not as a class induce relugolix metabolism; the relevant concern is P-gp inhibition increasing exposure, so preemptively doubling the dose would be dangerous.
Option E: Option E is incorrect because relugolix does not need to be stopped for the entire hospitalization; the interaction is avoided by selecting an antiarrhythmic that does not strongly inhibit P-gp, allowing relugolix to continue.

6. A 76-year-old man with newly diagnosed metastatic hormone-sensitive prostate cancer requires androgen deprivation therapy. His history includes a myocardial infarction 3 months ago, heart failure with a left ventricular ejection fraction of 35%, and a prior ischemic stroke. His cardiologist asks the oncology team to select the androgen deprivation agent with the most favorable cardiovascular profile for this high-risk patient. Which of the following choices is best supported by the available evidence, and why?

A) Leuprolide depot, because long-acting agonist depots provide steadier testosterone suppression that lowers cardiovascular event rates compared with oral agents in men with established heart disease
B) Bicalutamide monotherapy, because avoiding pituitary suppression keeps testosterone normal and thereby spares the cardiovascular system the harms of hypogonadism while still controlling the cancer
C) Oral relugolix, because in a randomized trial comparing relugolix with leuprolide (the HERO trial), relugolix achieved effective castration and was associated with a substantially lower rate of major adverse cardiovascular events, supporting its preference in men with established cardiovascular disease
D) Any GnRH agonist depot, because randomized evidence shows that the specific androgen deprivation agent has no influence on cardiovascular outcomes, which depend solely on the depth of testosterone suppression
E) Degarelix is the only acceptable choice and relugolix must be avoided, because oral antagonists have been shown to increase cardiovascular events relative to agonist depots

ANSWER: C

Rationale:

This patient has multiple high-risk cardiovascular features — recent myocardial infarction, heart failure with reduced ejection fraction, and prior stroke — so the cardiovascular profile of the androgen deprivation agent matters. In the randomized HERO trial comparing oral relugolix with leuprolide in advanced prostate cancer, relugolix achieved effective, sustained castration and was associated with a substantially lower rate of major adverse cardiovascular events (MACE) than leuprolide. The cardiovascular advantage is attributed to relugolix's faster testosterone recovery kinetics and avoidance of some sustained agonist-associated metabolic effects. Applying this evidence, oral relugolix is the best-supported choice for this high-risk patient.

Option A: Option A is incorrect because long-acting agonist depots are not shown to lower cardiovascular events relative to antagonists; if anything, agonists are associated with greater cardiovascular risk than antagonists in high-risk patients, so the reasoning is backwards.
Option B: Option B is incorrect because bicalutamide monotherapy does not provide adequate suppression for metastatic prostate cancer and is not appropriate primary therapy; it does not keep testosterone normal in a protective way (it tends to raise serum testosterone), and it is not a cardiovascular risk-reduction strategy.
Option D: Option D is incorrect because the choice of agent does influence cardiovascular outcomes; agonists and antagonists are not equivalent despite producing similar castrate testosterone, as shown by the MACE difference in the HERO trial.
Option E: Option E is incorrect because oral relugolix is an appropriate antagonist choice in high cardiovascular-risk patients and was associated with fewer cardiovascular events than leuprolide; the claim that oral antagonists increase cardiovascular events relative to agonists is not supported by the evidence.

7. A 7-year-old girl with central precocious puberty has been receiving leuprolide depot 7.5 mg intramuscularly every 4 weeks for 6 months. Despite therapy, her breast development has continued to progress and her growth velocity remains accelerated. A GnRH stimulation test shows a stimulated LH peak of 4.8 IU/L (IU per liter) at 40 minutes. Which of the following best interprets these findings and indicates the appropriate next step?

A) The stimulated LH of 4.8 IU/L confirms adequate suppression; the continued progression indicates peripheral (gonadotropin-independent) precocious puberty, and the leuprolide should be discontinued
B) The stimulated LH of 4.8 IU/L is above the target of below 2 IU/L that defines adequate HPG axis suppression; combined with the continued clinical progression, this indicates inadequate suppression, and the dose should be increased or the dosing interval shortened, followed by repeat confirmation
C) The stimulated LH of 4.8 IU/L confirms adequate suppression, and the continued breast development and accelerated growth are expected during the first year of therapy and require no change
D) The result indicates oversuppression of the HPG axis, and the leuprolide dose should be reduced to allow controlled pubertal progression
E) GnRH stimulation testing is invalid for assessing suppression in children on depot agonists; an unstimulated random LH should be used instead, and no change should be made based on this result

ANSWER: B

Rationale:

In central precocious puberty, adequacy of hypothalamic-pituitary-gonadal (HPG) axis suppression on depot GnRH agonist therapy is confirmed by a stimulated LH peak below 2 IU/L (IU per liter) after GnRH or GnRH agonist stimulation, typically at 30 to 60 minutes. This patient's stimulated LH of 4.8 IU/L exceeds that threshold, indicating inadequate suppression — and the biochemical finding is corroborated clinically by continued breast development and persistently accelerated growth velocity. The appropriate response is to intensify therapy by increasing the dose or shortening the dosing interval, then reconfirm adequate suppression with repeat stimulation testing.

Option A: Option A is incorrect because a stimulated LH of 4.8 IU/L does not confirm adequate suppression (the target is below 2 IU/L), and the picture is consistent with inadequately suppressed central precocious puberty rather than peripheral precocious puberty; discontinuing leuprolide would worsen the situation.
Option C: Option C is incorrect because a stimulated LH of 4.8 IU/L is above the suppression target, and the continued progression is a sign of treatment failure, not an expected and acceptable finding requiring no change.
Option D: Option D is incorrect because a stimulated LH of 4.8 IU/L reflects insufficient, not excessive, suppression; reducing the dose would worsen the inadequate control and further accelerate pubertal progression.
Option E: Option E is incorrect because GnRH (or GnRH agonist) stimulation testing is the standard, valid method to confirm suppression adequacy in children on depot agonist therapy, with a stimulated peak LH below 2 IU/L as the accepted criterion.

8. A 29-year-old man with Kallmann syndrome (anosmia, absent puberty, low LH, low FSH, low testosterone, intact pituitary on imaging) has been treated with testosterone gel for several years with good control of libido and energy. He and his partner now wish to conceive. He is surprised to learn that his current treatment is unlikely to permit fertility. Which of the following is the most appropriate change in management to restore his fertility?

A) Increase the testosterone gel dose to raise serum testosterone further, since higher systemic testosterone will drive spermatogenesis more effectively in hypogonadotropic men
B) Continue testosterone gel and add a GnRH agonist depot, because combined therapy maximizes intratesticular androgen production needed for spermatogenesis
C) Begin a GnRH antagonist such as degarelix to relieve receptor desensitization, allowing the pituitary to recover gonadotropin secretion and restore fertility
D) Begin a continuous (non-pulsatile) GnRH infusion, because steady receptor occupancy provides the most reliable stimulation of pituitary gonadotropin output for fertility
E) Discontinue testosterone replacement and begin pulsatile GnRH therapy via a portable pump delivering GnRH every 60 to 120 minutes (or alternatively exogenous gonadotropin therapy), because physiologic pulsatile stimulation of the intact pituitary restores LH and FSH secretion and intratesticular testosterone, inducing spermatogenesis, whereas exogenous testosterone suppresses gonadotropins and spermatogenesis

ANSWER: E

Rationale:

In Kallmann syndrome, an isolated form of hypogonadotropic hypogonadism, the defect is deficient pulsatile GnRH delivery while the pituitary gonadotrophs are intact. Fertility-restoring strategies are pulsatile GnRH therapy — a portable pump delivering small GnRH doses every 60 to 120 minutes to mimic physiologic hypothalamic secretion, which stimulates LH and FSH and thereby raises intratesticular testosterone and supports spermatogenesis — or alternatively exogenous gonadotropin therapy. Crucially, exogenous testosterone replacement must be discontinued, because systemic testosterone suppresses pituitary LH and FSH through negative feedback, lowering intratesticular testosterone and shutting down sperm production. Pulsatile GnRH therapy induces spermatogenesis adequate for conception in roughly 75 to 80% of treated hypogonadotropic men.

Option A: Option A is incorrect because raising systemic testosterone does not drive spermatogenesis; sperm production depends on high intratesticular testosterone generated by gonadotropin stimulation, and exogenous testosterone actually suppresses the gonadotropin drive required for sperm production.
Option B: Option B is incorrect because continuing testosterone suppresses gonadotropins, and a GnRH agonist depot produces continuous (non-pulsatile) receptor occupancy that downregulates the receptor and further suppresses the axis — the opposite of what is needed.
Option C: Option C is incorrect because degarelix is a GnRH antagonist that blocks the receptor and suppresses gonadotropins; it would deepen the deficiency, not restore fertility.
Option D: Option D is incorrect because continuous GnRH stimulation causes receptor downregulation and suppression of gonadotropins (the mechanism of agonist depots); only pulsatile delivery maintains gonadotropin secretion and supports fertility.

9. A 74-year-old man has received continuous leuprolide depot for prostate cancer for 16 months. He takes calcium and vitamin D. His baseline DEXA showed a femoral neck T-score of -1.5, and a repeat scan now shows -2.2. Two years ago he sustained a wrist fracture after a fall from standing height. Which of the following is the most appropriate bone-protective management?

A) Continue calcium and vitamin D alone, since supplementation is sufficient to prevent fractures in all men on androgen deprivation therapy regardless of baseline bone density or fracture history
B) Begin low-dose testosterone supplementation to protect bone, accepting a small risk of disease progression because the bone benefit outweighs the oncologic risk
C) Defer additional bone therapy until the patient sustains a vertebral or hip fracture, since prophylactic treatment before a major fracture has no proven benefit in men on androgen deprivation therapy
D) Initiate a bone-protective agent such as zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months, because this patient has multiple risk factors — a low baseline T-score, a prior fragility fracture, progressive bone loss despite supplementation, and prolonged androgen deprivation therapy
E) Stop the leuprolide and rely on intermittent androgen deprivation therapy, because treatment holidays alone fully restore bone mineral density and eliminate the need for any bone-targeted drug

ANSWER: D

Rationale:

This patient has multiple converging indications for bone-protective pharmacotherapy beyond calcium and vitamin D: a low baseline T-score (-1.5, below -1.0), a prior fragility fracture (wrist fracture after a fall from standing height), documented progressive bone loss to -2.2 despite supplementation, and prolonged (more than 12 months) androgen deprivation therapy (ADT). In this setting, zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months are standard agents, with denosumab having a strong evidence base for reducing fracture risk in men on ADT. Initiating one of these is the appropriate management.

Option A: Option A is incorrect because calcium and vitamin D alone are not sufficient in a high-risk patient who has already shown progressive bone loss and has a prior fragility fracture; supplementation is foundational but inadequate by itself here.
Option B: Option B is incorrect because testosterone supplementation is contraindicated in prostate cancer; it would stimulate tumor growth, and bone protection in this setting is achieved with non-hormonal agents, not testosterone.
Option C: Option C is incorrect because the standard of care in high-risk patients is to initiate bone-protective therapy prophylactically rather than waiting for a major fracture; vertebral and hip fractures carry substantial morbidity and mortality, and this patient's multiple risk factors justify treatment now.
Option E: Option E is incorrect because ADT-related bone loss is not fully reversible with treatment holidays, and intermittent ADT is a strategy for selected non-metastatic biochemically recurrent disease, not a substitute for bone-targeted therapy in a high-risk patient who needs ongoing castration.

10. A 64-year-old man underwent radical prostatectomy 3 years ago. He now has a biochemical recurrence with a slowly rising PSA, and recent imaging shows no evidence of metastatic disease. He is started on leuprolide depot, reaches an undetectable PSA nadir at 8 months, and his testosterone is suppressed to 16 ng/dL. He is troubled by fatigue, hot flashes, and loss of libido and asks whether he can take breaks from therapy. Which of the following best describes his candidacy for intermittent androgen deprivation therapy and the supporting rationale?

A) He is an appropriate candidate for intermittent androgen deprivation therapy: in men with biochemically recurrent, non-metastatic prostate cancer who achieve a good PSA nadir, intermittent therapy provides overall survival comparable to continuous therapy while allowing partial testosterone recovery during off-cycles that can mitigate fatigue, hot flashes, and other long-term effects of sustained hypogonadism
B) He is not a candidate, because intermittent androgen deprivation therapy is contraindicated in any patient with a rising PSA, as each treatment holiday accelerates the emergence of castration-resistant disease and significantly worsens survival
C) He is a candidate only if he first develops radiographic metastases, because intermittent therapy has proven survival benefit exclusively in metastatic disease
D) He is not a candidate because intermittent therapy requires the use of an oral GnRH antagonist; depot agonists cannot be used because testosterone recovery after a depot is too slow to permit any meaningful off-cycle
E) He is a candidate, but intermittent therapy should be started immediately from the outset of treatment rather than after achieving a PSA nadir, because beginning treatment holidays before full suppression preserves testicular function and speeds testosterone recovery

ANSWER: A

Rationale:

The strongest evidence for intermittent androgen deprivation therapy (ADT) — demonstrating overall survival comparable to continuous ADT — applies to men with biochemically recurrent, non-metastatic prostate cancer who achieve a good PSA nadir on therapy. This patient fits precisely: PSA-only recurrence after prostatectomy, no radiographic metastases, and an undetectable PSA nadir on ADT. Intermittent therapy allows partial testosterone recovery during off-cycles, which can mitigate the long-term consequences of sustained hypogonadism that are troubling him — fatigue, hot flashes, sexual dysfunction, and also metabolic and bone effects — without compromising survival. He is therefore an appropriate candidate.

Option B: Option B is incorrect because intermittent ADT does not significantly worsen survival in biochemically recurrent non-metastatic disease; randomized data show comparable overall survival, and guideline bodies support it as an option in this setting.
Option C: Option C is incorrect because the comparable-survival evidence for intermittent ADT applies specifically to biochemically recurrent non-metastatic disease, not to metastatic disease, where continuous ADT is standard; he does not need to develop metastases to qualify.
Option D: Option D is incorrect because intermittent ADT can be delivered with depot agonists, which were used in the majority of intermittent-therapy trials; although testosterone recovery is slower after a depot, off-cycle intervals are still feasible and beneficial.
Option E: Option E is incorrect because intermittent ADT protocols begin treatment holidays only after a confirmed PSA nadir and a period of sustained suppression; starting holidays before adequate suppression would provide neither the oncologic benefit of ADT nor meaningful off-cycle recovery.

11. A 77-year-old man with metastatic prostate cancer is about to begin GnRH agonist therapy. He takes sotalol for atrial fibrillation, recently completed levofloxacin for pneumonia, and uses ondansetron intermittently for nausea. His baseline ECG shows a QTc of 472 ms. The oncology team asks how to proceed safely with androgen deprivation in light of his cardiac history. Which of the following is the most appropriate management?

A) Proceed with GnRH agonist therapy without additional cardiac evaluation, because androgen deprivation therapy does not affect the QT interval and the patient's only relevant cardiac issue is his atrial fibrillation
B) Proceed with therapy and continue all of his QT-prolonging medications unchanged, because the only period of QT risk with GnRH agonists is the brief testosterone flare, which resolves once castrate levels are reached
C) Recognize that androgen deprivation therapy prolongs the QTc through testosterone suppression and adds to the effects of sotalol, the recently used fluoroquinolone, and ondansetron — all QT-prolonging agents — and that with a baseline QTc of 472 ms this represents a high-risk combination warranting cardiology input, review and possible modification of the QT-prolonging drugs, a baseline ECG, and repeat ECG after initiation
D) Conclude that a baseline QTc of 472 ms is reassuringly normal and requires no further evaluation, and that GnRH agonist therapy and the current medications can be continued together without ECG follow-up
E) Conclude that the QT risk arises solely from a direct effect of the GnRH agonist peptide on cardiac ion channels and that switching to a GnRH antagonist would eliminate the QT concern entirely

ANSWER: C

Rationale:

Androgen deprivation therapy (ADT)-induced testosterone suppression prolongs the cardiac action potential and increases the corrected QT interval (QTc) by roughly 10 to 20 milliseconds on average, and this is additive to the effects of concurrent QT-prolonging drugs. This patient stacks several risks: sotalol (a potent QT-prolonging antiarrhythmic), a recently completed fluoroquinolone (levofloxacin), ondansetron (a QT-prolonging antiemetic), and an already elevated baseline QTc of 472 ms. The appropriate management is to obtain cardiology input, review and possibly modify the QT-prolonging medications, obtain a baseline ECG, and repeat the ECG after ADT initiation. Patients with a baseline QTc above 500 ms or congenital long QT syndrome should not receive GnRH analogs without cardiology input.

Option A: Option A is incorrect because GnRH analog therapy does prolong the QT interval through testosterone suppression, so QT-related evaluation is relevant in this high-risk patient.
Option B: Option B is incorrect because the QT-prolonging effect of ADT is sustained throughout treatment, not limited to the flare phase; sustained hypogonadism maintains QTc prolongation, so the concurrent QT-prolonging drugs cannot simply be continued unchanged.
Option D: Option D is incorrect because a baseline QTc of 472 ms is already prolonged (above the typical upper limit of approximately 440 ms in men) and, combined with multiple QT-prolonging drugs, warrants active management and ECG follow-up rather than no evaluation.
Option E: Option E is incorrect because the QT effect of GnRH analogs is mediated by testosterone suppression — a class effect shared by agonists and antagonists — not by a direct peptide effect on cardiac ion channels; switching to an antagonist does not eliminate the QT concern, since antagonists also suppress testosterone.